The guidance cut and extended manufacturing disruption through Q2 2027 create headwinds for near-term revenue and margins. Monitor the October earnings call for details on insurance recoveries, production ramp timeline, and any further impact on product availability and market share.
Price Chart
Executive Summary
Integra LifeSciences pre-announced preliminary Q3 2026 revenue of ~$410-412M and adjusted EPS of $0.55-0.59, compared to consensus of $414.8M and $0.57. The company lowered full-year 2026 revenue guidance from $1.654-1.695B to $1.634-1.654B and adjusted EPS guidance from $2.40-2.50 to $2.30-2.40, citing a July flooding event at its Cincinnati facility that disrupted manufacturing and supply. While the EPS beat is modest, the revenue miss and guidance cut are negative signals, partially offset by expected insurance recoveries and strong cash flow guidance.
Key Financial Metrics
Key Facts
- Preliminary Q3 2026 revenue of ~$410-412M vs consensus $414.8M (miss)
- Preliminary Q3 2026 adjusted EPS of $0.55-0.59 vs consensus $0.57 (beat at midpoint)
- Full-year 2026 revenue guidance lowered from $1.654-1.695B to $1.634-1.654B
- Full-year 2026 adjusted EPS guidance lowered from $2.40-2.50 to $2.30-2.40
- July flooding at Cincinnati facility negatively impacted Q3 revenue by ~$7M and expected to impact Q4 by $15-20M
- Full manufacturing operations at Cincinnati facility expected to return in Q2 2027
- Company expects >$85M operating cash flow in Q3 and ~$190-200M for full year 2026
- Insurance recoveries expected to mitigate substantial portion of earnings impact
Financial Impact
Revenue guidance cut by ~$20-41M at midpoint; adjusted EPS guidance cut by $0.10 at midpoint; Q3 revenue miss of ~$3-5M vs consensus; flooding impact of ~$22-27M combined Q3+Q4
Risk Factors
- Extended production disruption beyond Q2 2027 could further pressure revenue and margins
- Insurance recoveries may be delayed or lower than expected, limiting earnings offset
- Customer attrition or market share loss due to supply constraints from the Cincinnati facility
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3373786 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $11.84 | awaiting T+5 | — | $12.13 (−2.41%) |
Oct 19, 2026 6d ago | 8-K | $13.33 | awaiting T+5 | — | $12.13 (−9.04%) |
Oct 14, 2026 12d ago | Court Ruling | $13.53 $12.33 | ▼ −8.91% | ▼ −7.89% | $12.13 (−10.38%) |
Oct 13, 2026 12d ago | 3 | $13.18 $11.84 | ▼ −10.13% | ▼ −10.59% | $12.13 (−7.97%) |
Oct 9, 2026 16d ago | 8-K | $13.98 $13.45 | ▲ +3.79% | ▲ +2.30% | $12.13 (+13.27%) |
Oct 6, 2026 20d ago | Press Release | $13.32 | awaiting T+5 | — | $12.13 (−8.97%) |
Oct 2, 2026 24d ago | 8-K | $12.68 $13.44 | ▼ −5.99% | ▼ −4.83% | $12.13 (+4.38%) |
Oct 2, 2026 24d ago | Press Release | $12.68 $13.44 | ▼ −5.99% | ▼ −4.83% | $12.13 (+4.38%) |
Sep 8, 2026 6w ago | 8-K | $16.26 $15.71 | ▼ −3.38% | ▼ −2.72% | $12.13 (−25.43%) |
May 8, 2026 24w ago | 8-K | $13.97 $14.11 | ▲ +1.00% | ▲ +1.09% | $12.13 (−13.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers